Journal of Diagnostics Concepts & Practice ›› 2022, Vol. 21 ›› Issue (06): 669-676.doi: 10.16150/j.1671-2870.2022.06.002
• Experts forum • Previous Articles Next Articles
Received:
2022-10-03
Online:
2022-12-25
Published:
2023-04-23
Contact:
ZHANG Chao
E-mail:chaozhang@tmu.edu.cn
CLC Number:
ZHANG Chao, GAO Xue. Advances in clinical diagnosis of secondary progressive multiple sclerosis[J]. Journal of Diagnostics Concepts & Practice, 2022, 21(06): 669-676.
[1] |
Inojosa H, Proschmann U, Akgün K, et al. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition[J]. J Neurol, 2021, 268(4):1210-1221.
doi: 10.1007/s00415-019-09489-5 |
[2] |
Weinshenker B G, Bass B, Rice G P, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability[J]. Brain, 1989, 112 (Pt 1):133-146.
doi: 10.1093/brain/112.1.133 URL |
[3] |
Healy L M, Stratton J A, Kuhlmann T, et al. The role of glial cells in multiple sclerosis disease progression[J]. Nat Rev Neurol, 2022, 18(4):237-248.
doi: 10.1038/s41582-022-00624-x pmid: 35190704 |
[4] |
Yong H Y F, Yong V W. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis[J]. Nat Rev Neurol, 2022, 18(1):40-55.
doi: 10.1038/s41582-021-00581-x |
[5] |
Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis[J]. Nat Rev Neurol, 2012, 8(11):647-656.
doi: 10.1038/nrneurol.2012.168 pmid: 23007702 |
[6] |
Correale J, Gaitán M I, Ysrraelit M C, et al. Progressive multiple sclerosis: from pathogenic mechanisms to treatment[J]. Brain, 2017, 140(3):527-546.
doi: 10.1093/brain/aww258 pmid: 27794524 |
[7] |
Oki S. Eomes-expressing T-helper cells as potential target of therapy in chronic neuroinflammation[J]. Neurochem Int, 2019, 130:104348.
doi: 10.1016/j.neuint.2018.11.023 URL |
[8] |
Peruzzotti-Jametti L, Willis C M, Hamel R, et al. Metabolic Control of Smoldering Neuroinflammation[J]. Front Immunol, 2021, 12:705920.
doi: 10.3389/fimmu.2021.705920 URL |
[9] |
Jäckle K, Zeis T, Schaeren-Wiemers N, et al. Molecular signature of slowly expanding lesions in progressive multiple sclerosis[J]. Brain, 2020, 143(7):2073-2088.
doi: 10.1093/brain/awaa158 pmid: 32577755 |
[10] |
Dal-Bianco A, Grabner G, Kronnerwetter C, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging[J]. Acta Neuropathol, 2017, 133(1):25-42.
doi: 10.1007/s00401-016-1636-z pmid: 27796537 |
[11] |
Gillen K M, Mubarak M, Nguyen T D, et al. Significance and In Vivo Detection of Iron-Laden Microglia in White Matter Multiple Sclerosis Lesions[J]. Front Immunol, 2018, 9:255.
doi: 10.3389/fimmu.2018.00255 pmid: 29515576 |
[12] |
Mehta V, Pei W, Yang G, et al. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions[J]. PLoS One, 2013, 8(3):e57573.
doi: 10.1371/journal.pone.0057573 URL |
[13] |
Popescu B F, Frischer J M, Webb S M, et al. Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions[J]. Acta Neuropathol, 2017, 134(1):45-64.
doi: 10.1007/s00401-017-1696-8 pmid: 28332093 |
[14] |
Lassmann H. Targets of therapy in progressive MS[J]. Mult Scler, 2017, 23(12):1593-1599.
doi: 10.1177/1352458517729455 URL |
[15] |
Choi I Y, Lee P, Adany P, et al. In vivo evidence of oxi-dative stress in brains of patients with progressive multiple sclerosis[J]. Mult Scler, 2018, 24(8):1029-1038.
doi: 10.1177/1352458517711568 URL |
[16] |
Rawji K S, Gonzalez Martinez G A, Sharma A, et al. The Role of Astrocytes in Remyelination[J]. Trends Neurosci, 2020, 43(8):596-607.
doi: S0166-2236(20)30124-7 pmid: 32620289 |
[17] |
Faissner S, Plemel J R, Gold R, et al. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies[J]. Nat Rev Drug Discov, 2019, 18(12):905-922.
doi: 10.1038/s41573-019-0035-2 pmid: 31399729 |
[18] |
Reali C, Magliozzi R, Roncaroli F, et al. B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis[J]. Brain Pathol, 2020, 30(4):779-793.
doi: 10.1111/bpa.v30.4 URL |
[19] |
Lassmann H. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis[J]. Front Immunol, 2019, 9:3116.
doi: 10.3389/fimmu.2018.03116 URL |
[20] |
Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology[J]. Brain, 2007, 130(Pt 4):1089-1104.
doi: 10.1093/brain/awm038 pmid: 17438020 |
[21] |
Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis[J]. Brain Pathol, 2004, 14(2):164-174.
doi: 10.1111/j.1750-3639.2004.tb00049.x pmid: 15193029 |
[22] |
Aloisi F, Serafini B, Magliozzi R, et al. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look[J]. Brain, 2010, 133(Pt 12):e157.
doi: 10.1093/brain/awq223 URL |
[23] |
Moccia M, Haider L, Eshaghi A, et al. B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 9(1):e1108.
doi: 10.1212/NXI.0000000000001108 URL |
[24] |
Gardner C, Magliozzi R, Durrenberger P F, et al. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats[J]. Brain, 2013, 136(Pt 12):3596-3608.
doi: 10.1093/brain/awt279 pmid: 24176976 |
[25] | Raveney B J E, Sato W, Takewaki D, et al. Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis[J]. Proc Natl Acad Sci U S A, 2021, 118(11):e2021818118. |
[26] |
Raveney B J, Oki S, Hohjoh H, et al. Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation[J]. Nat Commun, 2015, 6:8437.
doi: 10.1038/ncomms9437 pmid: 26436530 |
[27] | Levite M. Glutamate, T cells and multiple sclerosis[J]. J Neural Transm (Vienna), 2017, 124(7):775-798. |
[28] |
Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis[J]. J Neurol Neurosurg Psychiatry, 2014, 85(1):67-75.
doi: 10.1136/jnnp-2012-304333 pmid: 23486991 |
[29] | Ciron J, Gueguen A, Al K A, et al. Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteria[J]. Rev Neurol (Paris), 2022. |
[30] |
Katz S I, Krieger S, Farrell C, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis[J]. Mult Scler, 2014, 20(12):1654-1657.
doi: 10.1177/1352458514521517 URL |
[31] |
Rojas J I, Patrucco L, Alonso R, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina[J]. Mult Scler, 2021, 27(4):579-584.
doi: 10.1177/1352458520924586 URL |
[32] |
Cree B, Hollenbach J A, Bove R, et al. Silent progression in disease activity-free relapsing multiple sclerosis[J]. Ann Neurol, 2019, 85(5):653-666.
doi: 10.1002/ana.25463 pmid: 30851128 |
[33] |
Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis[J]. Brain, 2016, 139(Pt 9):2395-2405.
doi: 10.1093/brain/aww173 pmid: 27401521 |
[34] |
Filippi M, Preziosa P, Langdon D, et al. Identifying Progression in Multiple Sclerosis: New Perspectives[J]. Ann Neurol, 2020, 88(3):438-452.
doi: 10.1002/ana.v88.3 URL |
[35] |
Magliozzi R, Fadda G, Brown R A, et al. "Ependymal-in" Gradient of Thalamic Damage in Progressive Multiple Sclerosis[J]. Ann Neurol, 2022, 92(4):670-685.
doi: 10.1002/ana.26448 pmid: 35748636 |
[36] |
Kapoor R, Smith K E, Allegretta M, et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis[J]. Neurology, 2020, 95(10):436-444.
doi: 10.1212/WNL.0000000000010346 pmid: 32675076 |
[37] |
Högel H, Rissanen E, Barro C, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity[J]. Mult Scler, 2020, 26(2):210-219.
doi: 10.1177/1352458518819380 URL |
[38] |
Filippi M, Preziosa P, Barkhof F, et al. Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review[J]. JAMA Neurol, 2021, 78(3):351-364.
doi: 10.1001/jamaneurol.2020.4689 pmid: 33315071 |
[39] | Klineova S, Lublin F D. Clinical Course of Multiple Sclerosis[J]. Cold Spring Harb Perspect Med, 2018, 8(9). |
[40] | Preziosa P, Pagani E, Meani A, et al. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression[J]. Neurol Neuroimmunol Neuroinflamm, 2022, 9(2). |
[41] |
Dal-Bianco A, Grabner G, Kronnerwetter C, et al. Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI[J]. Brain, 2021, 144(3):833-847.
doi: 10.1093/brain/awaa436 pmid: 33484118 |
[42] |
Ontaneda D. Progressive Multiple Sclerosis[J]. Continuum (Minneap Minn), 2019, 25(3):736-752.
doi: 10.1212/CON.0000000000000727 pmid: 31162314 |
[43] |
Genovese A V, Hagemeier J, Bergsland N, et al. Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis[J]. Radiology, 2019, 293(2):424-433.
doi: 10.1148/radiol.2019190306 pmid: 31549947 |
[44] |
Sucksdorff M, Matilainen M, Tuisku J, et al. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis[J]. Brain, 2020, 143(11):3318-3330.
doi: 10.1093/brain/awaa275 pmid: 33006604 |
[45] |
Cree B, Arnold D L, Chataway J, et al. Secondary Progressive Multiple Sclerosis: New Insights[J]. Neurology, 2021, 97(8):378-388.
doi: 10.1212/WNL.0000000000012323 pmid: 34088878 |
[46] | Nylund M, Sucksdorff M, Matilainen M, et al. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET[J]. Brain Commun, 2022, 4(1):b301. |
[47] |
Varhaug K N, Torkildsen Ø, Myhr K M, et al. Neurofilament Light Chain as a Biomarker in Multiple Sclerosis[J]. Front Neurol, 2019, 10:338.
doi: 10.3389/fneur.2019.00338 pmid: 31024432 |
[48] |
Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa[J]. Clin Chem Lab Med, 2016, 54(10):1655-1661.
doi: 10.1515/cclm-2015-1195 pmid: 27071153 |
[49] | Comabella M, Sastre-Garriga J, Carbonell-Mirabent P, et al. Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis[J]. J Neurol Neurosurg Psychiatry, 2022. |
[50] |
Edwards K R, Kamath A, Button J, et al. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers[J]. Mult Scler Relat Disord, 2021, 51:102861.
doi: 10.1016/j.msard.2021.102861 URL |
[51] |
Barro C, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis[J]. Brain, 2018, 141(8):2382-2391.
doi: 10.1093/brain/awy154 pmid: 29860296 |
[52] |
Salzer J, Svenningsson A, Sundström P. Neurofilament light as a prognostic marker in multiple sclerosis[J]. Mult Scler, 2010, 16(3):287-292.
doi: 10.1177/1352458509359725 URL |
[53] |
Sun M, Liu N, Xie Q, et al. A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis[J]. Mult Scler Relat Disord, 2021, 51:102870.
doi: 10.1016/j.msard.2021.102870 URL |
[54] |
Groen K, Lechner-Scott J, Pohl D, et al. Can serum glial fibrillary acidic protein(GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis[J]. Mult Scler Relat Disord, 2021, 50:102931.
doi: 10.1016/j.msard.2021.102931 URL |
[55] |
Saraste M, Bezukladova S, Matilainen M, et al. Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI[J]. Mult Scler Relat Disord, 2021, 50:102810.
doi: 10.1016/j.msard.2021.102810 URL |
[56] |
Choi I Y, Lee P, Hughes A J, et al. Longitudinal changes of cerebral glutathione(GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis[J]. Mult Scler, 2017, 23(7):956-962.
doi: 10.1177/1352458516669441 URL |
[57] |
Cristofanilli M, Gratch D, Pagano B, et al. Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes[J]. Mult Scler, 2017, 23(13):1707-1715.
doi: 10.1177/1352458516684022 URL |
[1] | CHEN Hong, SHEN Yinzhong. Progress in diagnosis and treatment of human immunodeficiency virus infection/acquired immune deficiency syndrome complicated with tuberculosis [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 530-534. |
[2] | XIE Xiaoling, MA Siyu, WU Xi, LU Yeling, WANG Xuefeng, DING Qiulan. Molecular pathogenesis of two novel splice site mutations of F8 in hemophilia A [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(01): 32-37. |
[3] | LUO Li, ZHOU Jiru, GUO Yuhang, LI Yuying, HU Mingdong. Application of microteaching method in teaching of clinical diagnosis [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 561-563. |
[4] | LIU Jingwen, WU Qiu-liang. Significance of detection of p16 and Ki-67 in diagnosis of cervical intraepithelial lesions [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(02): 195-198. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||